Navigation Links
Amira Initiates Phase I Clinical Trial of Novel DP2 Antagonist
Date:4/20/2009

Trial Will Evaluate Safety, Proof of Mechanism of a Potential Oral Antagonist for the Treatment of Asthma and COPD

SAN DIEGO, April 20 /PRNewswire/ -- Amira Pharmaceuticals, Inc., announced today the initiation of a Phase I clinical study of AM211, its internally discovered oral drug candidate for the treatment and control of inflammatory and allergic diseases linked to the arachidonic acid pathway.

AM211 is an oral, selective antagonist of the receptor DP2, which recent studies have shown to be a potential target for the treatment of asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. The Phase I study is designed to obtain safety and proof of mechanism data for AM211.

"There remains a great deal of unmet medical need in asthma and COPD, and we look forward to exploring AM211's potential as a new treatment option," said Isabelle DeArmond, M.D., Vice President Clinical Development. "We may also explore AM211 in other inflammatory diseases based on the safety and proof of mechanism data from our Phase I studies."

DP2 is also known as CRTH2 or chemoattractant receptor-homologous molecule expressed on Th2 lymphocytes. DP2 is a high affinity receptor for prostaglandin D2 and, in humans, is implicated in Th2-dependent allergic inflammation.

"The start of the AM211 clinical studies marks another impressive milestone in our company's short existence. Our small but effective team has been able to bring three distinct molecules into the clinic in less than four years," said Bob Baltera, Amira's Chief Executive Officer. "We look forward to continuing this pace as we advance our next program for idiopathic pulmonary fibrosis toward the clinic."

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of compounds
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Amira Pharmaceuticals Hires Industry Veteran for CFO Position
2. Masimo Initiates Full Market Release of First-Ever Noninvasive Continuous Hemoglobin Monitor
3. Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer
4. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
5. Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain
6. QRxPharma Initiates Second Comparative Study for MoxDuo(TM) IR Dual-Opioid(TM) Pain Therapy
7. Isis Initiates Phase 1 Clinical Trial of SGLT2 Antisense Drug
8. Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
9. China Bio-Immunity Corporation Initiates Voluntary Recalls of Rabies Vaccines
10. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
11. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... provider of scientific, technical and medical information products and ... in Reproductive BioMedicine Online on ... abnormal chromosomal composition can be identified by the rate ... the risk of genetic abnormality without a biopsy. In ... retrospective study, using their predictive model to assess the ...
(Date:5/17/2013)... May 17, 2013 New ... most innovative thought leaders of the medical device ... East conference and expo, from June 18-20 in ... (Photo: http://photos.prnewswire.com/prnh/20130517/613829 ) , ... deliver industry professionals practical presentations and implementable solutions ...
(Date:5/17/2013)... May 17, 2013 /PRNewswire-iReach/ -- Aridis is pleased ... with Switzerland -based Kenta Biotech ... monoclonal antibody (mAb) products, and technologies. This asset ... for treatment of infections by common pathogens including ... , Pseudomonas aeruginosa , Acinetobacter baumannii ...
(Date:5/17/2013)... May 17, 2013 The paradigm of ... biological systems that can help predict the adverse and ... Sergey Stepaniants, Head of Computational Biology at the Genomics ... tools to ensure high-quality genomics when used as part ... applied to complex data sets to identify key clinical ...
Breaking Biology Technology:Breakthrough for IVF? 2Breakthrough for IVF? 3MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3
... Milestone Validates Approach, SAN FRANCISCO, January 22 ... its first clinical trial, a,proof-of-concept study that evaluated ... blocker. Rufinamide was discovered and,developed by Novartis and ... a,drug to treat a form of epilepsy. This ...
... B.V. announced today the closure of its Series ... Ventures., Progentix Orthobiology B.V. was established in ... products for clinical application,in bone regenerative surgery. Progentix ... biomaterial scaffolds that have the ability to,attract growth ...
... NorTech Venture,Capital Advisory Task Force reported in its inaugural ... generate and attract over $1.2 billion,in venture capital by ... companies,located in Northeast Ohio. According to the findings from ... region, to be,released in print mid February, Northeast Ohio ...
Cached Biology Technology:Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders 2Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders 3Progentix Orthobiology B.V. Closes Series A Financing Round 2Cleveland+ Region Attracts $318 Million in New Venture Investment in 2007 2Cleveland+ Region Attracts $318 Million in New Venture Investment in 2007 3Cleveland+ Region Attracts $318 Million in New Venture Investment in 2007 4Cleveland+ Region Attracts $318 Million in New Venture Investment in 2007 5
(Date:5/16/2013)... (May 17, 2013) Illustrating a commitment to ... American Gastroenterological Association (AGA) Research Foundation has announced ... Research Fellowship Award recipients. Supported by the National ... (NIDDK), this new award helps underrepresented minority students ... and nutrition research. , "By establishing this new ...
(Date:5/16/2013)... (Maximizing Access to Research Careers) Program has announced ... Developmental Biology (SDB) 72nd Annual Meeting in Cancun, ... meant to promote the entry of students, postdoctorates ... of the basic science community and to encourage ... 2013 Annual Meeting. , Awards are given to ...
(Date:5/16/2013)... the stability of today,s largest ice sheets in Greenland and ... ago, for example when Earth was going through a ... high sea level due to ice sheet collapse at that ... if the world,s largest ice sheets collapsed in the past, ... progressively warming world. , However, a new groundbreaking study ...
Breaking Biology News(10 mins):Underrepresented minority students receive fellowships in digestive disease and nutrition research 2World's biggest ice sheets likely more stable than previously believed 2
... Autism Speaks, the nation,s largest autism science and advocacy ... to investigate genetic and environmental risk factors for autism. ... multi-site studies focusing on a collaborative prospective study of ... who are at higher genetic risk for developing the ...
... legs learned to walk upright. So did Faith, ... "half-man" born without legs, grew naturally into a graceful hand-walker. ... Hensel live successfully with separate heads connected to a single ... to drive, swim, shuffle cards and play piano. In ...
... that modern lifestyle habits may play a bigger role than ... A review of the scientific evidence over the past 150 ... hygiene and health education, may override the effects of food ... a Supplement to the journal Obesity Reviews . ...
Cached Biology News:Autism Speaks funds $5 million to studies on genetic and environmental risk factors for autism 2Autism Speaks funds $5 million to studies on genetic and environmental risk factors for autism 3Autism Speaks funds $5 million to studies on genetic and environmental risk factors for autism 4Autism Speaks funds $5 million to studies on genetic and environmental risk factors for autism 5'Freaks' help scientist unravel nature and nurture 2'Freaks' help scientist unravel nature and nurture 3
Candida (IgG) -Ab EIA Sample Size: 5 l...
... Oxidized LDL (Competitive) EIA Principle: ... the monoclonal antibody 4E6. Oxidized LDL in the ... LDL bound to the microtiter well for the ... a washing st Sample Size: 25 ...
... RNase III, used with its manganese-containing reaction ... heterogeneous mix of short (1825 bp) interfering ... mammalian cells. 1.3 units (1 l) of ... 1 g of dsRNA into siRNA suitable ...
For cleavage of 6xHis tags from proteins containing a Factor Xa Protease recognition site Efficient 6xHis tag cleavage (greater than 90%), ...
Biology Products: